Leonard Bell, PhD

Originally a chemistry graduate, Dr. Leonard Bell initially worked in the industry as a peptide chemist. He then returned to university for his MSc (biomolecular technology) and PhD (“Interaction of Metal Ions and the β-Amyloid Peptide”). He subsequently returned to the industry after his postdoctoral work (“Peptides That Protect Cardiomyocytes From Anoxia and Reoxygenation”) and joined Labcorp Drug Development’s Biopharmaceutical CMC Services, specializing in large molecules.

Heather Watson

Heather Watson has 22 years of experience in the pharmaceutical and biotech industry, 14 of those in the CRO environment. Her areas of expertise include method development, validation and sample analysis of PK, PD and ADA (inclusive of NAb) methods, supporting both preclinical and clinical programs. She has experience with a variety of drug molecules including but not limited to ADCs, bi- or tri-specific Abs, biosimilars and gene therapies.

Agnes Zybura, PhD

Dr. Agnes Zybura has extensive knowledge in the fields of molecular neurobiology, pharmacology and biochemistry with expertise in signal transduction pathways, sodium channel biology, electrophysiology, fluorescent imaging techniques, cell culture and PCR-based assays. She serves as a QC scientist within the Molecular Bioanalysis group at Labcorp (Greenfield) where she is responsible for developing and validating qPCR-/dPCR-based assays in support of biodistribution and vector shedding studies in accordance with applicable regulatory guidelines (e.g., GLP, GCP/CLIA).

Guolan Wei

Guolan Wei has more than 20 years of experience in contract research organizations and biotechnology companies. She has expertise in regulated bioanalysis with LC-MS/MS assays and immunoassays (PK, ADA, neutralizing antibodies and biomarkers). 

Jill Uhlenkamp, PhD

Dr. Jill Uhlenkamp has nearly 20 years of experience in immunoassay development, with more than a decade of that time spent in regulated bioanalysis for drug development including in both biotech and CRO settings. She has developed or overseen development and validation for a wide range of bioanalytical assays. Her experience includes PK, ADA, NAb, and biomarker assays; preclinical and clinical studies; and small, large and oligonucleotide-based therapeutics in a range of matrices.

James Tunaley, PhD

Dr. James Tunaley has more than a decade of academic research and industrial lab experience in multiple fields, including genomics, genetic engineering, analytical chemistry, molecular biology, cell-based assays and protein expression and purification. He has expertise in supporting clients’ cell and gene therapy molecules through the preclinical and clinical stages of development with projects spanning GLP, GCP and GMP regulations.

Eric Thomas, PhD

Dr. Eric Thomas is the global director of method development and validation for LC-MS-based bioanalysis for Labcorp Bioanalytical Services.

Hazel Staton

Hazel Staton has a BSc from The University of Sheffield in biochemistry and graduated in 2007. Upon graduation, Hazel joined Labcorp Biopharmaceutical CMC Services as a QC analyst in the molecular biology department and progressed to become a QC scientist.

Daniel Sikkema, PhD

Dr. Daniel Sikkema brings more than 25 years of experience in the biopharmaceutical, vaccine and cell/gene therapy fields supporting oncology, neurosciences, respiratory, immunology and infectious disease. He has held positions of increasing responsibility at leading pharmaceutical and diagnostic instrumentation companies. In his career, he has contributed to the licensure of numerous vaccines and biopharmaceuticals, as well as the world’s first ex vivo cell/gene therapy product, leading to more than $150 billion in sales.

Keith Rennier, PhD

Dr. Keith Rennier has more than 13 years of biomedical research and development expertise in PCR, cell-based assays, signal transduction pathways and flow cytometry. His research has primarily focused on cellular mechanotransduction, tumor immunology and cancer biology.

He earned a PhD in biomedical engineering from Purdue University in 2015. As a postdoctoral research fellow at Washington University in St. Louis, Keith focused on assay development to delineate key oncogenic signaling pathways and immune cell recruitment in human tumors.